SBP 401
Alternative Names: SBP-401Latest Information Update: 03 Oct 2023
At a glance
- Originator Spark BioPharma
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 03 Oct 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis (unspecified route), prior to September 2023 (Spark BioPharma pipeline, September 2023)
- 03 Oct 2023 Preclinical trials in Idiopathic pulmonary fibrosis in South Korea (unspecified route), prior to September 2023 (Spark BioPharma pipeline, September 2023)
- 15 Dec 2021 Early research in Idiopathic pulmonary fibrosis in South Korea (unspecified route) before December 2021 (Spark BioPharma pipeline, December 2021)